University Hospital Motol, Prague, Czech Republilc   Report issue

Academic/Hospital Phase 2
Founded: Prague Czech Republic

Organization Overview

First Clinical Trial
2012
NCT03828123
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2013

Timeline

NOW
  • Now

Alternative names

Department of Neurology, University Hospital Motol, Prague, Czech Republic | Department of Spine Surgery, University Hospital Motol, Prague, Czech Republilc

Active Ingredients

Drugs in Phase 2 Trials (1)

bone marrow derived mesenchymal stem cells (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Amyotrophic Lateral Sclerosis (Phase 2)

Intervertebral Disc Degeneration (Phase 2)

Motor Neuron Disease (Phase 2)

Rotator Cuff Injuries (Phase 2)

Sclerosis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 1